Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 59


Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines.

Quan Y, Xu H, Kramer VG, Han Y, Sloan RD, Wainberg MA.

Virol J. 2014 Oct 6;11:177. doi: 10.1186/1743-422X-11-177.


Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency.

Bastarache SM, Mesplède T, Donahue DA, Sloan RD, Wainberg MA.

Viruses. 2014 Sep 19;6(9):3487-99. doi: 10.3390/v6093487.


Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.

Quashie PK, Mesplède T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA.

Antimicrob Agents Chemother. 2013 Dec;57(12):6223-35. doi: 10.1128/AAC.01835-13. Epub 2013 Sep 30. Erratum in: Antimicrob Agents Chemother. 2014 Jan;58(1):633.


Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Donahue DA, Bastarache SM, Sloan RD, Wainberg MA.

J Virol. 2013 Sep;87(17):9620-32. doi: 10.1128/JVI.01165-13. Epub 2013 Jun 26.


HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction.

Lisovsky I, Schader SM, Sloan RD, Oliveira M, Coutsinos D, Bernard NF, Wainberg MA.

Intervirology. 2013;56(4):258-64. doi: 10.1159/000348513. Epub 2013 May 8.


Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis.

Sloan RD, Kuhl BD, Mesplède T, Münch J, Donahue DA, Wainberg MA.

J Virol. 2013 Jul;87(14):8110-23. doi: 10.1128/JVI.00815-13. Epub 2013 May 15.


Harnessing the therapeutic potential of host antiviral restriction factors that target HIV.

Sloan RD, Wainberg MA.

Expert Rev Anti Infect Ther. 2013 Jan;11(1):1-4. doi: 10.1586/eri.12.146. No abstract available.


Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.

Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL.

Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8. doi: 10.1128/AAC.00591-12. Epub 2012 Jun 25.


Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.

Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, Tressler R, Sloan RD, Wainberg MA.

Antimicrob Agents Chemother. 2012 Aug;56(8):4154-60. doi: 10.1128/AAC.00409-12. Epub 2012 May 21.


Novel therapeutic strategies targeting HIV integrase.

Quashie PK, Sloan RD, Wainberg MA.

BMC Med. 2012 Apr 12;10:34. doi: 10.1186/1741-7015-10-34. Review.


The viral protein Tat can inhibit the establishment of HIV-1 latency.

Donahue DA, Kuhl BD, Sloan RD, Wainberg MA.

J Virol. 2012 Mar;86(6):3253-63. doi: 10.1128/JVI.06648-11. Epub 2012 Jan 11.


The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism.

Kuhl BD, Cheng V, Donahue DA, Sloan RD, Liang C, Wilkinson J, Wainberg MA.

PLoS One. 2011;6(11):e27660. doi: 10.1371/journal.pone.0027660. Epub 2011 Nov 14.


Vpu-mediated tetherin antagonism of ongoing HIV-1 infection in CD4(+) T-cells is not directly related to the extent of tetherin cell surface downmodulation.

Kuhl BD, Sloan RD, Donahue DA, Liang C, Wainberg MA.

Virology. 2011 Sep 1;417(2):353-61. doi: 10.1016/j.virol.2011.06.012. Epub 2011 Jul 14.


The role of unintegrated DNA in HIV infection.

Sloan RD, Wainberg MA.

Retrovirology. 2011 Jul 1;8:52. doi: 10.1186/1742-4690-8-52. Review.


Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef.

Sloan RD, Kuhl BD, Donahue DA, Roland A, Bar-Magen T, Wainberg MA.

J Virol. 2011 Mar;85(6):2828-36. doi: 10.1128/JVI.01854-10. Epub 2011 Jan 5.


Tetherin restricts direct cell-to-cell infection of HIV-1.

Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, Wainberg MA.

Retrovirology. 2010 Dec 24;7:115. doi: 10.1186/1742-4690-7-115.


HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.

Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA.

AIDS. 2010 Sep 10;24(14):2171-9. doi: 10.1097/QAD.0b013e32833cf265.


Neither ritonavir nor darunavir affect cell surface expression of tetherin or Vpu-mediated tetherin down-modulation.

Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, Wainberg MA.

AIDS. 2010 Jul 31;24(12):1970-2. doi: 10.1097/QAD.0b013e32833bfe3d. No abstract available.


Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.

Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA.

J Virol. 2010 Sep;84(18):9210-6. doi: 10.1128/JVI.01164-10. Epub 2010 Jul 7.


Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes.

Sloan RD, Donahue DA, Kuhl BD, Bar-Magen T, Wainberg MA.

Retrovirology. 2010 May 13;7:44. doi: 10.1186/1742-4690-7-44.

Items per page

Supplemental Content

Loading ...
Support Center